The complement system is strongly implicated in the development and progression of geographic atrophy (GA) and has emerged as an attractive therapeutic target.

In February, pegcetacoplan intravitreal injection (Syfovre, Apellis Pharmaceuticals), a complement inhibitor, gained FDA approval for the treatment of GA secondary to AMD, marking a significant milestone in the progress of therapeutics for AMD. This article reviews our understanding of the complement system, its role in GA, and current investigational therapies that target this system.

**THE COMPLEMENT SYSTEM AND GA**

The complement system serves as the first line of defense against invading pathogens by inducing cell lysis and enhancing the activity of the antibody-driven adaptive immune system (Figure 1). The three complement pathways (classical, alternative, and lectin) converge upon a shared terminal series of reactions that lead to the formation of the membrane attack complex (MAC) on target cell surfaces.1 MAC causes cell lysis, the major endpoint of the complement system. Byproducts of this enzyme cascade recruit leukocytes and tag pathogens for phagocytic destruction, while MAC itself can induce several localized inflammatory reactions.1 The potency of the complement system requires tight regulation to prevent local host tissue damage.

Chronic, low-grade inflammation is a primary driver of AMD and GA pathogenesis, and overactivity of the complement system has been specifically implicated.2,3 For example, several complement-related gene mutations are strongly associated with increased AMD risk, likely due to complement dysregulation within the retina.4 Accordingly, high concentrations of complement byproducts have been found in the plasma of patients with AMD, as well as within the retinal pigment epithelium (RPE) and photoreceptor outer segments in areas of GA.5 Complement byproducts have also been found in high concentrations within drusen,6 raising the possibility that drusen may represent biomarkers of a localized, complement-mediated inflammatory process driving GA pathogenesis at the RPE-Bruch membrane junction.6

Therefore, the complement system is an attractive target for GA therapy (Figure 2) with the most promising strategy involving the inhibition of C3 and C5 activation.7,8

**THERAPEUTIC TARGETS**

**Common Pathway Target: C3**

Pegcetacoplan is a C3 inhibitor that binds and prevents activation of C3 by C3 convertase, blocking activation of downstream effectors and halting the cascade’s progression.

The phase 3 OAKS and DERBY trials enrolled patients with BCVA ≥ 24 ETDRS letters (approximately 20/320 Snellen equivalent) and total GA area between 2.5 mm² and 17.5 mm².9 In the OAKS trial, both monthly and every-other-month treatment arms showed statistically significant reductions in GA growth (22% and 18%, respectively) at 24 months when compared with sham.10 DERBY data followed a similar trend with reductions in GA growth of 19% and 16%, respectively.10 A phase 3 extension study evaluating the long-term safety of pegcetacoplan for up to 36 months is underway.11

Another C3 inhibitor, NGM621 (NGM Biopharmaceuticals),

**AT A GLANCE**

- Chronic, low-grade inflammation is thought to be a primary driver of AMD and geographic atrophy (GA) pathogenesis, and overactivity of the complement system has been specifically implicated.
- The most promising interventions for GA currently involve inhibiting the activation of C3 and C5.
- There is some concern for increased risk of exudative transformation with complement inhibition for GA.
is a monoclonal antibody that was recently evaluated in the phase 2 CATALINA trial. Although the study failed to reach its primary endpoint, a post-hoc analysis suggests a statistically significant reduction in GA growth rate (21.9% and 16.8% with every 4- and 8-week injections, respectively) among a subgroup of eyes exhibiting a narrower range of baseline GA area than the trial inclusion criteria.

Other C3 inhibitors in development include CB 2782-PEG (Catalyst Biosciences) and KNP-301 (Kanaph Therapeutics), both of which are currently in preclinical testing.

**Terminal Pathway Targets: C5 and MAC**

C5 is another attractive therapeutic target due to its key role in initiating the formation of MAC. The C5 inhibitor avacincaptad pegol (Zimura, Iveric Bio) is a pegylated RNA aptamer that binds and prevents activation of C5. The phase 2/3 GATHER1 trial found a statistically significant decrease in mean rate of GA area growth with monthly injections of 2 mg and 4 mg avacincaptad pegol at 12 months compared with sham (27.4% and 27.8% reduction in rate of square root of GA area growth, respectively).

The ongoing GATHER2 trial is evaluating monthly injections of 2 mg avacincaptad pegol for 12 months, followed by monthly or every-other-month injections for 23 months. The trial met its primary endpoint, demonstrating a statistically significant 14.3% reduction in mean rate of GA area growth (square root transformed) with monthly treatment compared with sham. The FDA has accepted the company’s new drug application, granting priority review status with a Prescription Drug User Fee Act goal date in August.

MAC inhibition is also a therapeutic strategy for GA. HMR59 (Hemera Biosciences) is a gene therapy that induces expression of the endogenous MAC-inhibitory protein CD59; the safety of its intravitreal administration in GA is the subject of an ongoing phase 1 trial.

**Alternative Pathway Targets**

The alternative pathway accounts for more than 80% of terminal pathway activation and ultimate MAC formation, making it a prime therapeutic target. The pathway is constitutively activated by spontaneous hydrolysis of C3 into soluble C3a and C3b fragments, which then participate...
in a positive feedback amplification loop by creating C3 convertase. The activity of this amplification loop is tightly regulated by several complement factors (CF), including CFH, CFI, CFD, and CFB. Selectively targeting these complement factors in the alternative pathway is theoretically advantageous due to the preservation of host defense via intact classical and lectin pathways.

CFH plays the most prominent role in downregulating alternative pathway activity, degrading C3b and inactivating C3 convertase. CFH deficiency has been strongly implicated in the development of GA, and genetic mutations reducing CFH expression represent the strongest genetic risk factors for AMD, increasing the risk by up to seven-fold.Δ1,Δ2

CFI, an important cofactor of CFH in the degradation of C3b, has been targeted with GT005 (Gyroscope Therapeutics/Novartis), a gene therapy designed to induce local overexpression of CFI following subretinal or suprachoroidal administration.Δ3 Interim data from the phase 1/2 FOCUS trial suggests that GT005 is well tolerated in GA, while two phase 2 trials are ongoing: HORIZON and EXPLORE.Δ4,Δ5 An additional, observational, long-term follow-up cohort trial, ORACLE, is also in progress.Δ6

The alternative pathway amplification loop may also be targeted directly by inhibiting CFB and CFD. A CFD inhibitor,
ACH-4471 (Danicopan, Alexion Pharmaceuticals), is being studied as an oral therapy for GA in a phase 2 trial. CFB is being targeted by subcutaneous administration of IONIS-FB-LRx (Ionis Pharmaceuticals), an antisense oligonucleotide that reduces CFB protein expression by degrading CFB messenger RNA, the phase 2 GOLDEN trial is active.

**Classical Pathway Target: C1**

The classical pathway has also been a therapeutic target of some interest. This pathway is initiated by antibody-antigen complexes binding and activating the C1 complex. ANX007 (Annexon) is an intravitreally-injected antigen-binding fragment designed to inhibit C1q, the functional component of C1. The phase 2 ARCHER trial is assessing the safety of ANX007 in GA, with topline data expected this year.

**SAFETY CONSIDERATIONS**

Complement inhibition for GA has generally been well tolerated in clinical trials. However, there is some concern for increased risk of exudative degeneration with anti-complement therapy. In the combined phase 3 pegcetacoplan trial data, new-onset exudation was noted in 11.9% of the monthly groups, 6.7% in the every-other-month groups, and 3.1% in the sham groups at 24 months. Patients at greatest risk were those with exudative AMD in the contralateral eye and those exhibiting the OCT double-layer sign—a potential marker of subclinical type 1 macular neovascularization.

The GATHER1 and GATHER2 trials also demonstrated a slightly increased risk of exudative transformation with avacincaptad pegol therapy. The mechanism by which complement inhibition may increase the risk of exudation and neovascular disease remains uncertain, and further research is ongoing. Additional theoretical concerns have been raised regarding endophthalmitis risk with intravitreal injection of immunosuppressive complement inhibitor therapies. However, endophthalmitis rates in the pegcetacoplan and avacincaptad pegol trials have reassuringly been similar to or lower than those reported with other intravitreal therapies.

**FUTURE PERSPECTIVES**

Our approach to AMD is rapidly evolving with a growing array of promising treatment options. The development of sustained release technologies and novel drug delivery methods will hopefully increase the durability and lessen the burden on our patients. With ongoing research and innovation, we are confident that new treatments for AMD will continue to advance, helping preserve vision and improve the quality of life of countless individuals around the world.  